Antivirals Market By Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Antivirals Market
Antivirals Market Analysis: By Type (Hepatitis-C, HIV, Herpes, Hepatitis-B, Influenza & Other Antivirals); By Action (DNA polymerase inhibitors, NS3 Protease inhibitors, Reverse transcriptase inhibitors and Others) – With Forecast (2016-2021)
Report Code : HCR 0130
Updated Date: 25 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Antivirals– Market Overview
2. Executive Summary 
3. Antivirals– Market Landscape 
   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Antivirals– Market Forces
   4.1. Market Drivers 
   4.2. Market Constraints
   4.3. Market Challenges
   4.4. Attractiveness of the Antivirals Market 
      4.4.1. Power of Suppliers
      4.4.2. Power of Customers 
      4.4.3. Threat of New Entrants 
      4.4.4. Threat of Substitution
      4.4.5. Degree of Competition
5. Antivirals Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis 
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Antivirals Market– By Type
   6.1. Hepatitis-C antivirals
   6.2. HIV antivirals
   6.3. Herpes antivirals
   6.4. Hepatitis-B antivirals
   6.5. Influenza antivirals
   6.6. Others
7. Antivirals Market– By Actions
   7.1. DNA polymerase inhibitors
   7.2. NS3 Protease inhibitors
   7.3. Reverse transcriptase inhibitors 
   7.4. Others
8. Antivirals Market– By Geography
   8.1. Introduction
   8.2. Global Study
   8.3. Americas
      8.3.1. North America 
      8.3.2. Brazil
      8.3.3. Argentina
      8.3.4. Others 
   8.4. Europe
      8.4.1. U.K.
      8.4.2. France
      8.4.3. Germany
      8.4.4. Others
   8.5. APAC
      8.5.1. China
      8.5.2. Japan
      8.5.3. India
      8.5.4. Others
   8.6. ROW
9. Antivirals Market Entropy
   9.1. New Product Launches
   9.2. M&As, Collaborations, JVs and Partnerships
10. Company Profiles 
   10.1. Novartis AG
   10.2. Gilead Sciences Inc.
   10.3. Merck
   10.4. Johnson and Johnson
   10.5. GlaxoSmithKline
   10.6. Abbott Laboratories
   10.7. AstraZeneca AB
   10.8. BoehringerIngelheim Corporation
   10.9. Schering-Plough
   10.10. Roche
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
11. Appendix
   11.1. Abbreviations
   11.2. Sources
   11.3. Research Methodology
   11.4. Bibliography
   11.5. Compilation of Expert Insights
   11.6. Disclaimer
Antivirals are drugs that are used to treat viral infections. While a majority of antivirals are used for treating specific viral infections, there are a few broad-spectrum antivirals to treat other viral infections. As opposed to antibiotics that actually destroy the target pathogen, antivirals only inhibit the growth of the pathogen. Antivirals have the advantage of not causing any side effects and focus on inibiting the replication of the virus. An increase in the disease afflicted population across the globe is one of the major drivers for this market. Apart from this, increasing levels of awareness coupled with the launch of newer and more effective drugs, this market has tremendous opportunities in emerging economies. The antiviral market is expected to grow at a steady and healthy growth rate till the end of the forecast period considered in this report.  Expiry of patents is another factor providing opportunities for this market. Factors that include government policies can prove to be challenges in this market. 

The report also provides an exhaustive overview of antiviral research and development pipeline. A huge amount of research and development is underway to extend the range of antivirals to treat other pathogens. Also, with the tendency of viruses to mutate and become drug resistant, the need of the hour is to develop and refresh the pipeline of antivirals with new therapies.  A section on patent analysis is also included. 

Antivirals Market

Antiviral drugs are used in the treatment of  HIV, herpes viruses, the hepatitis B and C viruses, and influenza A and B viruses. The global antivirals market is expected to be dominated by HIV antivirals. According to the WHO and UNAIDS estimates, 36.7 million people were living with HIV globally at the end of 2015. In 2015, approximately 2.1 million people became newly infected and 1.1 million died of HIV-related causes. 

The Antivirals market can be segmented on the basis of type as:
  • HIV Antivirals
  • Hepatitis-C Antivirals
  • Herpes Antivirals
  • Influenza Antivirals
  • Hepatitis-B Antivirals
  • Other Antivirals 

In terms of actions, the Antivirals market has been segmented across the following:
  • DNA polymerase inhibitors
  • NS3 Protease inhibitors
  • Reverse transcriptase inhibitors 
The market has been segmented based on the following geographies:
  • North America
  • South America
  • APAC
  • Europe
  • Middle East 
  • Africa

Sample Companies Profiled in this Report are: 
  • GlaxoSmithKline plc
  • Merck & Co
  • Johnson and Johnson
  • Novartis International AG
  • Gilead Sciences Inc
  • 10+
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports